A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL).

Trial Profile

A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Navitoclax (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms FRANC
  • Sponsors Genentech
  • Most Recent Events

    • 10 Dec 2012 Preliminary results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov. (Parent trial: NCT01087151).
    • 07 May 2012 Additional trial location added as reported by ClinicalTrials.gov. (Parent trial: NCT01087151)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top